Lumexa Imaging Holdings, Inc. (LMRI) AI Stock Analysis
LMRI AI stock analysis summary
AI ResearchLumexa Imaging Holdings, Inc. (LMRI) operates outpatient diagnostic imaging centres across the United States. Revenue reached $1.02B in FY2025 and $1.04B over the trailing twelve months, though net income remained negative at -$47.1M in FY2025. The company carries $975.4M in total debt against $69.7M in cash and short-term investments as of June 30, 2026.
- Market cap
- $1.04B
- Revenue (TTM)
- $1.04B
- P/E
- —
- 1Y return
- — S&P 500 16.8%
- Avg. target
- $17.67 63.9% vs last close
Bull case
- Revenue expanded at a 2-year CAGR of 4.6% to reach $1.02B in FY2025, up 7.8% from FY2024.
- Analysts project a swing to profitability with an estimated FY2026 EPS of $0.77, representing estimated EPS growth of 326.5%.
- All 10 analyst ratings are favorable, comprising 8 Strong Buy and 2 Buy recommendations, with a mean price target of $17.67.
Bear case
- The company reported net losses in each of the past three fiscal years, including -$47.1M in FY2025 and trailing twelve month net losses yielding an EPS of -$0.37.
- Free cash flow declined from $13.0M in FY2024 to -$6.4M in FY2025 as operating cash flow dropped to $17.1M.
- Balance sheet leverage is elevated, with total debt of $975.4M and net debt of $905.6M against $69.7M in cash and short-term investments as of June 30, 2026.
What Lumexa Imaging does
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. Founded in 2018 and headquartered in Raleigh, North Carolina, the company employs 5,000 people. It delivers outpatient medical imaging services including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). In addition, Lumexa Imaging provides X-ray, ultrasound, and mammography diagnostic and screening imaging services through its network of outpatient facilities.
Growth and profitability
Revenue rose from $935.9M in FY2023 to $948.9M in FY2024, representing 1.4% revenue growth, and expanded 7.8% to $1.02B in FY2025, recording a 2-year revenue CAGR of 4.6%. Gross margin moved from 10.6% in FY2023 to 10.1% in FY2024 and 11.5% in FY2025, while operating margin went from 2.4% in FY2023 to 5.8% in FY2024 before dipping to 2.6% in FY2025. Net losses narrowed from -$122.2M in FY2023 and -$94.1M in FY2024 to -$47.1M in FY2025, yielding an EPS of -$0.02. For the latest quarter ended June 30, 2026, quarterly revenue growth was 5.1% year-over-year, while trailing twelve month revenue stood at $1.04B with an operating margin of 3.2% and EPS of -$0.37.
Balance sheet and cash flow
As of June 30, 2026, Lumexa Imaging held $69.7M in cash and short-term investments alongside total debt of $975.4M, resulting in net debt of $905.6M. Total assets stood at $1.81B and shareholders' equity was $615.1M, yielding a debt-to-equity ratio of 1.59 and a current ratio of 1.44. In FY2025, operating cash flow was $17.1M, down from $40.7M in FY2024, and free cash flow turned to -$6.4M. Capital expenditures used $23.5M of cash in FY2025.
Valuation and performance
At a last close of $10.78 on October 16, 2026, Lumexa Imaging traded at a market cap of $1.04B and an enterprise value of $1.88B. Its price-to-sales ratio of 1.0x was below the 4.1x median of its US-listed Healthcare peers, while its EV to EBITDA multiple of 14.2x was higher than the peer median of 12.0x. The company also trades at a price-to-book multiple of 1.6x. The stock has posted a year-to-date return of -41.7% and closed 5.3% below its 200-day average, while the S&P 500 (SPY) returned 16.8% over the past year.
What analysts expect
Wall Street coverage consists of 8 Strong Buy ratings and 2 Buy ratings, with 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $17.67, which sits 63.9% above the last close of $10.78. For the fiscal year ending December 31, 2026, analysts estimate revenue of $1.07B and EPS of $0.77, representing estimated EPS growth of 326.5%. Lumexa Imaging beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 11, 2026.
Key risks and what to watch
- The debt-to-equity ratio of 1.59 and net debt of $905.6M leave limited liquidity cushion with cash and short-term investments at $69.7M.
- Operating margin remains thin at 2.6% in FY2025 and 3.2% over the trailing twelve months, well below the US-listed Healthcare peer median of 14.0%.
- The company has missed expectations frequently, posting EPS beats in only 1 of the last 4 quarters.
- The stock experienced a year-to-date return of -41.7% and traded 5.3% below its 200-day average as of October 16, 2026.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this LMRI AI stock analysis
This page is an AI-written research summary of Lumexa Imaging Holdings, Inc. (LMRI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: LMRI income statement, LMRI balance sheet, LMRI key metrics, LMRI analyst forecast, LMRI chart. See the LMRI stock overview for the latest quote and news.
LMRI AI stock analysis FAQ
What does Lumexa Imaging Holdings do?
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. It provides outpatient services including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography.
When was Lumexa Imaging's IPO and where is it traded?
Lumexa Imaging completed its IPO in 2025 and trades on the NASDAQ under the ticker symbol LMRI.
Is Lumexa Imaging currently profitable?
No, Lumexa Imaging posted a net loss of -$47.1M in FY2025 and a trailing twelve month net loss margin of -2.7%, though analysts estimate EPS of $0.77 for FY2026.
How much debt does Lumexa Imaging carry?
As of June 30, 2026, Lumexa Imaging reported total debt of $975.4M and net debt of $905.6M, alongside cash and short-term investments of $69.7M.
When is Lumexa Imaging's next earnings report?
Lumexa Imaging's next earnings date is scheduled for November 11, 2026.